J. Sailstad

发表

Quantitative Bioanalytical Methods Validation and Implementation: Best Practices for Chromatographic and Ligand Binding Assays

Vinod P. Shah, C. T. Viswanathan, Jeffrey Sailstad, 2007 .

Key Elements of Bioanalytical Method Validation for Macromolecules

V. Shah, M. Rose, J. Sailstad, 2007 .

Enfuvirtide Cerebrospinal Fluid (CSF) Pharmacokinetics and Potential use in Defining CSF HIV-1 Origin

D. Kuritzkes, R. Price, S. Deeks, 2008, Antiviral therapy.

Ligand Binding Assays in Drug Development

O. Laterza, R. Bowsher, W. Nowatzke, 2013 .

Application of commercial research-grade biomarker assays in drug development: is it time to create 'pharmaceutical-grade' kits?

Masood U Khan, Ronald R Bowsher, R. Bowsher, 2012, Bioanalysis.

2012 white paper on recent issues in bioanalysis and alignment of multiple guidelines.

Sam H Haidar, Lauren F. Stevenson, Lauren F Stevenson, 2012, Bioanalysis.

A phase I and pharmacokinetic study of 1843U89, a noncompetitive inhibitor of thymidylate synthase, in patients with advanced solid malignancies.

D. V. Von Hoff, L. Smetzer, H. Burris, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

A Phase I and Pharmacokinetic Study of 1843 U 89 , a Noncompetitive Inhibitor of Thymidylate Synthase , in Patients with Advanced Solid Malignancies 1

L. Smetzer, H. Burris, D. V. Hoff, 2001 .

Fit-for-Purpose Method Development and Validation for Successful Biomarker Measurement

Viswanath Devanarayan, Russell Weiner, Chad Ray, 2006, Pharmaceutical Research.

The pharmacokinetics and pharmacodynamics of the prostacyclin analog 15AU81 in the anesthetized beagle dog.

J. Sailstad, R. Steffen, M. J. Mcnulty, 1993, Prostaglandins, leukotrienes, and essential fatty acids.

Radioimmunoassay for the chemical stable prostacyclin analog, 15AU81: a preliminary pharmacokinetics study in the dog.

T. L. Page, J. W. Findlay, S. Chang, 1993, Prostaglandins, leukotrienes, and essential fatty acids.

Quantitative Bioanalytical Methods Validation and Implementation: Best Practices for Chromatographic and Ligand Binding Assays

C. T. Viswanathan, Patrick G. Swann, V. Shah, 2007, Pharmaceutical Research.

Clinical and Pharmacokinetic Profiles of Digoxin Immune Fab in Four Patients with Renal Impairment

J. W. Findlay, J. Sailstad, G. Dunham, 1991 .

Heterobiaryl human immunodeficiency virus entry inhibitors.

D. Bolognesi, S. Fisher, M. Greenberg, 2009, Journal of medicinal chemistry.

Workshop/conference report—Quantitative bioanalytical methods validation and implementation: Best practices for chromatographic and ligand binding assays

Vinod P. Shah, C. T. Viswanathan, Jeffrey Sailstad, 2007, The AAPS Journal.

Pre-existing anti–polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer

Jeffrey M. Sailstad, B. Sullenger, T. Povsic, 2015, The Journal of allergy and clinical immunology.

Immunofluorometric Assay for Lamotrigine (Lamictal) in Human Plasma

J. W. Findlay, J. Sailstad, J. Findlay, 1991, Therapeutic drug monitoring.

Method Validation and Measurement of Biomarkers in Nonclinical and Clinical Samples in Drug Development: A Conference Report

H. Soares, R. Pietrusko, V. Quarmby, 2005, Pharmaceutical Research.

Workshop on Bioanalytical Methods Validation for Macromolecules: Summary Report

Krys J. Miller, Michael Geier, Steve J. Swanson, 2001, Pharmaceutical Research.

Treatment of digoxin intoxication in a renal failure patient with digoxin-specific antibody fragments and plasmapheresis.

J. Sailstad, G. Rabetoy, J. Findlay, 1990, American journal of nephrology.

Pseudoephedrine and triprolidine in plasma and breast milk of nursing mothers.

R. Welch, R. Butz, J. T. Warren, 1984, British journal of clinical pharmacology.

Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer.

N Franklin Adkinson, Jeffrey Sailstad, Paul W Armstrong, 2016, The Journal of allergy and clinical immunology.

A White Paper—Consensus and Recommendations of a Global Harmonization Team on Assessing the Impact of Immunogenicity on Pharmacokinetic Measurements

K. Sonehara, H. Myler, B. Gorovits, 2014, The AAPS Journal.

A White Paper—Consensus and Recommendations of a Global Harmonization Team on Assessing the Impact of Immunogenicity on Pharmacokinetic Measurements

K. Sonehara, H. Myler, B. Gorovits, 2014, The AAPS Journal.

Understanding and mitigating impact of immunogenicity on pharmacokinetic assays.

J. Sailstad, M. Golob, Joleen T. White, 2011, Bioanalysis.

Clinical and pharmacokinetic profiles of digoxin immune Fab in four patients with renal impairment.

J. Sailstad, G. Dunham, N. M. Allen, 1991, DICP : the annals of pharmacotherapy.

The pharmacokinetics of digoxin immune fab total digoxin and free digoxin in patients with renal impairment

M. Chow, J. Kluger, R. Colucci, 1989 .

Insights in the application of research-grade diagnostic kits for biomarker assessments in support of clinical drug development: bioanalysis of circulating concentrations of soluble receptor activator of nuclear factor kappaB ligand.

Ronald R Bowsher, R. Bowsher, Jeffrey M Sailstad, 2008, Journal of pharmaceutical and biomedical analysis.

Technical aspects of inductively coupled plasma bioanalysis techniques.

J. Wieling, J. Sailstad, Phillip Wang, 2013, Bioanalysis.

Calibration Curves in Quantitative Ligand Binding Assays: Recommendations and Best Practices for Preparation, Design, and Editing of Calibration Curves

B. Gorovits, Perceval Sondag, J. Sailstad, 2017, The AAPS Journal.

Workshop/conference report—Quantitative bioanalytical methods validation and implementation: Best practices for chromatographic and ligand binding assays

C. T. Viswanathan, Patrick G. Swann, V. Shah, 2007, The AAPS Journal.

Technical aspects of inductively coupled plasma bioanalysis techniques.

J. Wieling, J. Sailstad, Phillip Wang, 2013, Bioanalysis.